Radiopharm Theranostics Limited(RADX)Earnings, Financials & Key Ratios
RADX•NASDAQ
$4.24
Price updated Jul 7, 2026
AboutRadiopharm Theranostics Limited engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical needs. It develops RAD 204, a programmed death-ligand 1 (PD-L1) for the treatment of non-small cell lung cancer (NSCLC); RAD 202, a human epidermal growth factor receptor 2 (HER2) to treat breast cancer and other solid tumors; and RAD 301, a diagnostic radiopharmaceutical targeting avß6 integrin in pancreatic ductal adenocarcinoma patients. The company also develops RAD 302, an avß6-integrin targeting agent for the treatment of multiple cancer types; RAD 101 and RAD 102 for brain metastases; RAD 402 to treat advanced prostate cancer; and RV01 for multiple solid tumors. It has strategic agreement with Lantheus Holdings, Inc. to advance the clinical development of radiopharmaceuticals. The company was incorporated in 2021 and is based in Carlton, Australia.Show more
- Revenue$4M+1114.3%
- EBITDA-$38M-13.9%
- Net Income-$38M+20.0%
- EPS (Diluted)-5.28+85.3%
- Gross Margin1.08%-98.9%
- EBITDA Margin-1050.43%+90.6%
- Operating Margin-1050.63%+91.4%
- Net Margin-1055.27%+93.4%
- ROE-109.2%+17.0%
RADX Price & Volume
Radiopharm Theranostics Limited (RADX) stock price & volume — 10-year historical chart
Loading chart...
Clinical Development Costs Outpace Revenue Growth Trajectory
Investment Thesis • Updated N/A
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Clinical trial funding dependency
Key Thesis Takeaways
- Radiopharm Theranostics operates as a pre-commercial entity where a 1114% revenue surge is overshadowed by an unsustainable -1050% operating margin.
- The company's reliance on non-recurring milestone payments and a limited $29M cash runway necessitates ongoing external capital, creating significant dilution risk for shareholders.
- Investors should monitor the clinical validation of the RAD 301 pipeline, as the current business model remains highly sensitive to the successful execution of early-stage trials.
Verdict Logic
the company's reliance on external funding to bridge a -1050% operating margin and a limited $29M cash runway presents a high risk of shareholder dilution before clinical milestones are achieved.
RADX Growth Metrics
Radiopharm Theranostics Limited (RADX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years643.76%
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-
Return on Capital
10 Years-50.08%
5 Years-50.08%
3 Years-57.97%
Last Year-60.59%
Peers Comparison
Key metrics vs top competitors for Radiopharm Theranostics Limited (RADX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $4.24 | $33.42M | -1.16 | 1114.27% | -1055.27% | -109.2% | — | |
| $6.01 | $2.19B | 19.21 | 43.31% | 7.82% | 7.42% | — | |
| $8.44 | $8.02M | -0.16 | — | — | -99.39% | — | |
| $103.41 | $6.73B | 30.33 | 0.5% | 18.05% | 24.33% | — | |
| $3.50 | $145.75M | -1029.41 | 10.37% | 52.16% | — | — | |
| $17.42 | $42.04M | -0.38 | -3.5% | -624.59% | -16.12% | — |
Compare RADX vs Peers
Radiopharm Theranostics Limited (RADX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when RADX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
RADX Frequently Asked Questions
Radiopharm Theranostics Limited (RADX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Radiopharm Theranostics Limited's revenue?
Radiopharm Theranostics Limited (RADX) reported $3.6M in revenue for fiscal year 2024. This represents a 41044% increase from $0.0M in 2021.
How fast is Radiopharm Theranostics Limited growing?
Radiopharm Theranostics Limited (RADX) grew revenue by 1114.3% over the past year. This is strong growth.
Is RADX profitable?
Radiopharm Theranostics Limited (RADX) reported a net loss of $38.3M for fiscal year 2024.
Dividend & Returns
What is RADX's return on equity?
Radiopharm Theranostics Limited (RADX) has a return on equity (ROE) of -109.2%. Negative ROE indicates the company is unprofitable.
What is Radiopharm Theranostics Limited's free cash flow?
Radiopharm Theranostics Limited (RADX) had negative free cash flow of $36.6M in fiscal year 2024, likely due to heavy capital investments.